Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Beam

Cathie Wood Just Bet $26 Million on Broadcom Stock. Should You Buy AVGO Too?

Cathie Wood bets on Broadcom while shorting major market names in a week of activity.

Barchart

“A complete, compact desktop solution”: Blackstar launches the Beam Mini – the world’s first amplifier to natively support Neural Amp Modeling

The potentially game-changing practice amp grants players access to over 35 amps and cabs – as well as Tone3000’s massive user-generated tone library

Guitar World

“Uncompromising tone whenever inspiration strikes”: Blackstar unveils the Beam Mini – it’s portable, desktop-friendly, and as the first guitar amp to allow players to load Neural Amp Modeller captures, it's a game-changer too

NAMM 2026: Out this spring, the Beam Mini gives guitarists access to more than 200,000 neural captures created by the Tone3000 commuity

MusicRadar

From analysis to the latest developments in health,
read the most diverse news in one place.

Marshall Heston 60 review: The Sonos Beam killer we've been waiting for?

Marshall's smaller Heston soundbar is a new contender

Late-stage payments company Modern Treasury acquires stablecoin startup Beam for $40 million

The deal comes one year after the fintech giant Stripe said it would acquire the stablecoin firm Bridge.

Fortune

Beam Global Gets Buy Rating With 101% Upside Potential

For investors willing to take a chance on a penny stock that is still chasing profitability, Beam Global has many points in its favor.

MarketBeat

Beam Global Scores Major Win As US Government Extends Procurement Contract

Beam Global (NASDAQ:BEEM) shares traded higher on Tuesday after the company announced the renewal of its Multiple Award Schedule contract with the U.S. General Services Administration.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease

Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle cell disease.

Benzinga

Catalyst for change or community menace? What’s next for Australia’s e-bike revolution

Share e-bikes have been used in 8.9m trips covering 17.6m kilometres over 15 years. Where are they headed now?

The Guardian - AU

Curtains for originality? Theatre creatives on the West End romcom musical boom

IN FOCUS: As a musical based on the 2004 Adam Sandler-Drew Barrymore love story prepares for its West End debut, Isabel Dempsey surveys the current deluge of romcom remakes hitting the stage and asks industry folk whether the boom is helping or harming

The Independent UK

Google Beam 3D video conferencing could change your work calls forever

Google says Deloitte, Salesforce and Duolingo are all interest in Beam (Project Starline), but it won't be for consumers.

TechRadar

I tested two mid-range Dolby Atmos soundbars side-by-side, and the battle for your money has never been more competitive

The Sonos Beam and Sony Bravia Theater Bar 6 are two mid-range Dolby Atmos soundbars. How do they compare?

TechRadar

All jobs lost at subsea tech firm in Scotland as firm enters administration

ALL jobs have been lost at a UK subsea technology firm, with a base in Aberdeen, after it entered administration

The National (Scotland)

Major Knightsbridge office block next to Harrods gets green light despite privacy fears

Westminster says the 11-storey development at 1 Knightsbridge Green will offer office space to just under 2,000 workers and bring in millions of pounds worth of footfall

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

1 'Strong Buy' Penny Stock With 259% Upside Potential

BEEM stock has underperformed in 2024. Should you bet on a comeback year in 2025?

Benzinga

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains

Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results.

Barchart

Stock Index Futures Gain With U.S. Presidential Election in Focus, Economic Data and Earnings on Tap

December S&P 500 E-Mini futures (ESZ24) are up +0.21%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.27% this morning as investors braced for the closely contested U.S. presidential election, while also awaiting a new round of economic data and corporate earnings reports.

The Guardian - UK

Social workers in England begin using AI system to assist their work

Magic Notes tool records and analyses face-to-face meetings and suggests follow-up actions

Get all your
news in one place.

100’s of premium titles.
One news app.

The Canberra Times

E-scoot boot: A purple patch of mobility vanishes from Canberra streets

Beam e-scooters sent packing after government ban.

The Canberra Times

Beam to face big fines if its scooters don't get removed in time

Beam trying to refund customers who have subscriptions.

The Canberra Times

Get your scooters out of town: ACT govt kicks out Beam

Beam had 250 secret scooters on the streets of Canberra.

The Guardian - AU

Brisbane e-scooter operator Beam loses licence over alleged breach of daily cap

City council alleges cap on scooter numbers ‘systematically exceeded’ by 500 a day but company ‘disagrees’ with claims, saying it is ‘reviewing options’

The Canberra Times

Auckland 'deactivates' Beam e-scooters as ACT considers action

Will the ACT follow Auckland and axe Beam e-scooters from the streets?

The Canberra Times

Verbal street war over Canberra e-scooters

Neuron accuses Beam of 'reprehensible' conduct.

The Canberra Times

ACT govt investigating 'unethical' conduct by e-scooter operator Beam

Beam apologises for breaching vehicle caps, denies it was intentional.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations